Showing results (1-10 of 116) with videos related to
Sort By:
Pageof 12
Frontiers in Oncology|June 1, 2022
LKB1: Can We Target an Hidden Target? Focus on NSCLCGloriana Ndembe, Ilenia Intini, Elisa Perin, et al.Frontiers in Oncology|November 16, 2020
Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different MutationsMarika Colombo, Mirko Marabese, Giulia Vargiu, et al.American Journal of Cancer Research|January 8, 2021
Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell linesAlice Iezzi, Elisa Caiola, Marika Colombo, et al.American Journal of Cancer Research|March 23, 2026
Erratum: Molecular determinants of response to PI3K/AKT/mTOR and KRAS pathways inhibitors in NSCLC cell linesAlice Iezzi, Elisa Caiola, Marika Colombo, et al.Journal of Experimental & Clinical Cancer Research : CR|December 14, 2022
Isolation and characterization of two newly established thymoma PDXs from two relapses of the same patient: a new tool to investigate thymic malignanciesPaolo Mendogni, Roberta Affatato, Enrico Cabri, et al.Cells|July 29, 2020
Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine ExploitationElisa Caiola, Marika Colombo, Giovanna Sestito, et al.Journal of Experimental & Clinical Cancer Research : CR|January 2, 2024
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapyGloriana Ndembe, Ilenia Intini, Massimo Moro, et al.Cells|December 11, 2022
NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2)Marika Colombo, Federico Passarelli, Paola A Corsetto, et al.International Review of Cytology|September 5, 2002
Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patientsFaina Vikhanskaya, Massimo BrogginiPageof 12